GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: May 2, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | May 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-repurchase
TL;DR
GSK bought back some of its own stock on May 1st via Citigroup.
AI Summary
On May 1, 2025, GSK plc, through its corporate stockbroker Citigroup Global Markets Limited, purchased a number of its own ordinary shares. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine share repurchase announcement and does not indicate any significant new risks.
Key Players & Entities
- GSK plc (company) — Company making the share purchase
- Citigroup Global Markets Limited (company) — Corporate stockbroker executing the share purchase
- May 1, 2025 (date) — Date of the share purchase
FAQ
What was the exact number of GSK ordinary shares purchased on May 1, 2025?
The filing states that GSK purchased 'the following number of the Company's ordinary shares' but does not specify the exact quantity.
What was the total dollar amount spent on the share repurchase?
The filing does not disclose the total dollar amount of the share repurchase.
Who acted as GSK's corporate stockbroker for this transaction?
Citigroup Global Markets Limited acted as GSK's corporate stockbroker.
What is the nominal value of GSK's ordinary shares mentioned in the filing?
The ordinary shares are described as having a nominal value of 31¼ pence each.
Is this a new share issuance or a repurchase of existing shares?
This filing concerns a 'Transaction in own shares,' indicating a repurchase of existing shares.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 2, 2025 regarding GSK plc (GLAXF).